Hunterian Medicine
Advancing cures for genetic diseases with innovative CRISPR delivery technology
Advancing cures for genetic diseases with innovative CRISPR delivery technology
Hunterian Medicine is a biotech company founded in 2016 and based in Cambridge, Massachusetts. The company's slogan "Advancing cures for genetic diseases with innovative CRISPR delivery technology" encapsulates its focus on developing treatments for genetic diseases without FDA-approved therapies. Hunterian Medicine leverages the potential of CRISPR through its patented platform technology, which tackles the challenge of CRISPR delivery by enabling efficient, on-target delivery using a single adeno-associated virus (AAV).
The company operates in the biotechnology and health care industries, aiming to address the unmet medical needs arising from genetic diseases. Notably, Hunterian Medicine received a $300.00K grant investment on 27 May 2021 from the Cystic Fibrosis Foundation.
With its innovative approach and promising technology, Hunterian Medicine presents an intriguing opportunity for venture capitalists seeking to support advancements in genetic disease treatments. The company's focus on unmet medical needs and its successful track record in attracting funding make it a noteworthy player in the biotech landscape.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $300.00K | 1 |
|
27 May 2021 |
| Convertible Note | $3.48M | - | 11 Sep 2016 |
No recent news or press coverage available for Hunterian Medicine.
We care about your data, and we'd love to use cookies make your experience better.
